Temelimab 54 mg/kg ( DrugBank: Temelimab )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05049161 (ClinicalTrials.gov)	August 27, 2021	31/8/2021	A Long-term Extension of Study GNC-401	A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab	Multiple Sclerosis	Drug: Temelimab 18 mg/kg;Drug: Temelimab 36mg/kg;Drug: Temelimab 54 mg/kg	GeNeuro Innovation SAS	NULL	Recruiting	18 Years	55 Years	All	40	Phase 2	Sweden
2	NCT04480307 (ClinicalTrials.gov)	June 17, 2020	10/7/2020	Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: temelimab 18 mg/kg;Drug: temelimab 36 mg/kg;Drug: temelimab 54 mg/kg;Drug: Placebo	GeNeuro Innovation SAS	NULL	Active, not recruiting	18 Years	55 Years	All	41	Phase 2	Sweden